Pulmonx Corporation (LUNG)
NASDAQ: LUNG · Real-Time Price · USD
2.750
+0.190 (7.42%)
Nov 9, 2026, 3:29 PM EST - Market open
Pulmonx Revenue
Pulmonx had revenue of $22.84M in the quarter ending September 30, 2026, with 6.20% growth. This brings the company's total for the last twelve months to $88.78M, down -3.15% year-over-year. In the year 2025, Pulmonx had annual revenue of $90.50M with 8.01% growth. That makes Pulmonx the 23,609th largest company in the world by revenue and 3,372nd in the United States.
Revenue (ttm)
$88.78M
Revenue Growth
-3.15%
P/S Ratio
1.36
Revenue / Employee
$299,916
Employees
296
Market Cap
119.76M
Revenue by Geography
- United States 57.02M 63.0%
- Europe, Middle-East and Africa (EMEA) 26.99M 29.8%
- Asia Pacific 6.23M 6.9%
- Other International 260.00K 0.3%
Fiscal year ended Dec 31, 2025 See the full Pulmonx breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 90.50M | 6.71M | 8.01% |
| Dec 31, 2024 | 83.79M | 15.11M | 22.01% |
| Dec 31, 2023 | 68.68M | 15.01M | 27.98% |
| Dec 31, 2022 | 53.66M | 5.25M | 10.84% |
| Dec 31, 2021 | 48.42M | 15.68M | 47.91% |
| Dec 31, 2020 | 32.73M | 138.00K | 0.42% |
| Dec 31, 2019 | 32.60M | 12.59M | 62.94% |
| Dec 31, 2018 | 20.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Inogen | 355.06M |
| Quanterix | 153.41M |
| Outset Medical | 121.97M |
| Owlet | 114.41M |
| Apyx Medical | 59.57M |
| Nyxoah | 32.77M |
| MaxCyte | 31.05M |
| Hyperfine | 16.54M |
LUNG News
- 12 days ago - Pulmonx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Pulmonx price target raised to $4 from $2.50 at Stifel - TheFly
- 13 days ago - Pulmonx Earnings Call Transcript: Q3 2026 - Transcripts
- 13 days ago - Pulmonx Earnings release: Q3 2026 - Filings
- 13 days ago - Pulmonx Quarterly report: Q3 2026 - Filings
- 13 days ago - Pulmonx reports Q3 EPS (19c), consensus (26c) - TheFly
- 13 days ago - Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.55M - TheFly
- 13 days ago - Pulmonx Reports Third Quarter 2026 Financial Results - GlobeNewsWire